Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kJ/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
C-RAF (Homo sapiens (Human)) | BDBM410658![]() (US10377770, Example 491) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 0 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
C-RAF (Homo sapiens (Human)) | BDBM410542![]() (US10377770, Example 366) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 0 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
C-RAF (Homo sapiens (Human)) | BDBM410686![]() (US10377770, Example 519) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 0 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
C-RAF (Homo sapiens (Human)) | BDBM410317![]() (9-(5-(2-(1,1-difluoroethyl)isonicotinamido)-2-meth...) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 0 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
C-RAF (Homo sapiens (Human)) | BDBM410462![]() (US10377770, Example 284) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 0 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
C-RAF (Homo sapiens (Human)) | BDBM410479![]() (US10377770, Example 301) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 0 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
C-RAF (Homo sapiens (Human)) | BDBM410579![]() (US10377770, Example 404) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 0 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
C-RAF (Homo sapiens (Human)) | BDBM410437![]() (US10377770, Example 257) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 0 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
C-RAF (Homo sapiens (Human)) | BDBM410533![]() (US10377770, Example 357) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 0 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
C-RAF (Homo sapiens (Human)) | BDBM410536![]() (US10377770, Example 360) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 0 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
C-RAF (Homo sapiens (Human)) | BDBM410446![]() (US10377770, Example 267) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 0 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
C-RAF (Homo sapiens (Human)) | BDBM410438![]() (US10377770, Example 258) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 0 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
C-RAF (Homo sapiens (Human)) | BDBM410529![]() (US10377770, Example 353) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 0 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
C-RAF (Homo sapiens (Human)) | BDBM410464![]() (US10377770, Example 286) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 0 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
C-RAF (Homo sapiens (Human)) | BDBM410574![]() (US10377770, Example 398) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 0 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
C-RAF (Homo sapiens (Human)) | BDBM410615![]() ((rac)-N-(5-(7-hydroxy-1,2,5,5a,6,7-hexahydro-4H-[1...) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 0 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
C-RAF (Homo sapiens (Human)) | BDBM410510![]() (US10377770, Example 333) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 0 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
C-RAF (Homo sapiens (Human)) | BDBM410573![]() (US10377770, Example 397) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 0 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
C-RAF (Homo sapiens (Human)) | BDBM410256![]() ((rac)-N-(3-(1,2,4,4a,5,6-hexahydro-[1,4]oxazino[4,...) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.00100 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
C-RAF (Homo sapiens (Human)) | BDBM410352![]() (US10377770, Example 112) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <0.00200 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
C-RAF (Homo sapiens (Human)) | BDBM410384![]() (US10377770, Example 144) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.00200 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
C-RAF (Homo sapiens (Human)) | BDBM410342![]() (N-(3-((4aR,6R)-6-Hydroxy-1,2,4,4a,5,6-hexahydro-[1...) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <0.00200 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
C-RAF (Homo sapiens (Human)) | BDBM410350![]() (US10377770, Example 110) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.00200 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
C-RAF (Homo sapiens (Human)) | BDBM410356![]() (US10377770, Example 116 | rac-trans-2-(1,1-Difluor...) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <0.00200 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
C-RAF (Homo sapiens (Human)) | BDBM410277![]() ((rac)-N-(3-(6-hydroxy-6-methyl-1,2,4,4a,5,6-hexahy...) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.00200 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
C-RAF (Homo sapiens (Human)) | BDBM410387![]() (US10377770, Example 147) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.00300 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
C-RAF (Homo sapiens (Human)) | BDBM410381![]() (US10377770, Example 141) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.00400 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
C-RAF (Homo sapiens (Human)) | BDBM410393![]() (US10377770, Example 153) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.00500 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
C-RAF (Homo sapiens (Human)) | BDBM410357![]() (2-(1,1-Difluoroethyl)-N-(3-((4aR,5R)-5-(hydroxymet...) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.00500 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
C-RAF (Homo sapiens (Human)) | BDBM410358![]() (2-(1,1-Difluoroethyl)-N-(3-((4aR,5R)-5-(hydroxymet...) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.00500 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
C-RAF (Homo sapiens (Human)) | BDBM410362![]() (US10377770, Example 122 | rac-trans-N-(3-(5-(Hydro...) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.00500 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
C-RAF (Homo sapiens (Human)) | BDBM410231![]() ((trans)-2-(1,1-difluoroethyl)-N-(3-(6-hydroxy-1,2,...) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.00500 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
C-RAF (Homo sapiens (Human)) | BDBM410351![]() (US10377770, Example 111) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.00500 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
C-RAF (Homo sapiens (Human)) | BDBM410363![]() (US10377770, Example 123 | rac-trans-N-(3-(5-(Hydro...) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.00500 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
C-RAF (Homo sapiens (Human)) | BDBM410207![]() ((trans)-N-(3-(6-hydroxy-1,2,4,4a,5,6-hexahydro-[1,...) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.00600 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
C-RAF (Homo sapiens (Human)) | BDBM410349![]() (US10377770, Example 109) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.00600 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
C-RAF (Homo sapiens (Human)) | BDBM410306![]() (2-(1,1-difluoroethyl)-N-(3-(5-(hydroxymethyl)-1,2,...) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.00600 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
C-RAF (Homo sapiens (Human)) | BDBM410293![]() (N-(3-(5,5-bis(hydroxymethyl)-1,2,4,4a,5,6-hexahydr...) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.00600 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
C-RAF (Homo sapiens (Human)) | BDBM410399![]() (US10377770, Example 159) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.00700 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
C-RAF (Homo sapiens (Human)) | BDBM410223![]() (US10377770, Example 12) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.00700 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
C-RAF (Homo sapiens (Human)) | BDBM410281![]() (US10377770, Example 43 | US10377770, Example 44) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.00800 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
C-RAF (Homo sapiens (Human)) | BDBM410268![]() ((trans)-N-(3-(6-methoxy-1,2,4,4a,5,6-hexahydro-[1,...) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.00800 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
C-RAF (Homo sapiens (Human)) | BDBM410274![]() ((rac)-(cis)-N-(3-(6-hydroxy-1,2,4,4a,5,6-hexahydro...) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.00800 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
C-RAF (Homo sapiens (Human)) | BDBM410353![]() (US10377770, Example 113) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.00800 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
C-RAF (Homo sapiens (Human)) | BDBM410364![]() (US10377770, Example 124) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.00900 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
C-RAF (Homo sapiens (Human)) | BDBM410361![]() (N-(5-((4aR,5R)-5-(Hydroxymethyl)-1,2,4,4a,5,6-hexa...) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.00900 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
C-RAF (Homo sapiens (Human)) | BDBM410380![]() (US10377770, Example 140) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.00900 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
C-RAF (Homo sapiens (Human)) | BDBM410269![]() (US10377770, Example 34) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.00900 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
C-RAF (Homo sapiens (Human)) | BDBM410383![]() (US10377770, Example 143) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.00900 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
C-RAF (Homo sapiens (Human)) | BDBM410300![]() ((rac)-N-(3-(5-(hydroxymethyl)-1,2,4,4a,5,6-hexahyd...) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.00900 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ... | US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T | |||||||||||
More data for this Ligand-Target Pair |
Displayed 1 to 50 (of 457 total ) | Next | Last >> |